[5] Despite presenting its product as an alternative to other medications that work to treat obesity, the advertisement obscures the fact that Hims weight loss medications are unapproved, compounded products that have not been subject to clinical testing or FDA scrutiny and pose a higher risk to patients than FDA-approved drugs. [6] Most alarmingly, the commercial makes no mention of side-effects, warnings, or the potentially serious risks posed by any semaglutide product
PlexusDx's Precision Peptide Genetic Test identifies these pathways for $298, allowing clinicians to optimize your tirzepatide strategy based on your unique peptide biology rather than trial and error
careful dose titration with physician oversight minimizes discontinuation
More serious side effects including signs of kidney problems (such as change in the amount of urine), vision changes (such as decreased/blurred vision), signs of pancreatitis or gallbladder disease (such as nausea/vomiting that doesn`t stop, severe stomach/abdominal pain) should be reported to your doctor immediately
Call for More Research Many guidelines also mention the need for more research
Practical dosing comparison Both compounds use once-weekly subcutaneous injection